Close Menu

NEW YORK — MDNA Life Sciences said on Thursday that it has signed a Southeast Asian distribution deal for its PCR-based Mitomic Prostate Test (MPT) liquid biopsy assay with Mediwell Enterprise.

MPT is designed for the early detection of prostate cancer in advance of biopsy, independent of prostate-specific antigen levels and patient age, based on measurement of the 3.4 kb mitochondrial DNA deletion in plasma samples.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.